Our analyses have revealed that inhibition of CDK4/6 upregulates glutamine and fatty acid-oxidation-dependent mitochondrial metabolism in BRAF mutant melanoma cells, but they do not alter glycolysis nor the metabolic response to MAPK inhibitors. The gene discussed is BRAF; the disease is melanoma.